AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Viatris Inc.
Video analysis: VTRS
All videosNo video analysis for this stock yet. Request one from our team.
News: VTRS
Viatris: Strong Cash Generation And Pipeline Progress Keep The Re-Rating Story Alive
Viatris' Q2 showed better earnings quality, with adjusted net income and EPS up 11% while free cash flow doubled year-over-year. Deleveraging remains on track, while buybacks and dividends demonstrate that stronger cash generation is already supporting shareholder returns. Pipeline progress and new-product approvals provide additional growth optionality beyond the mature portfolio, with key Phase 3 assets approaching important milestones.
Viatris (VTRS) is a Top-Ranked Value Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Cavendish reiterates 'buy' rating on Shield Therapeutics after US deal with Viatris
Cavendish has reiterated its buy rating on Shield Therapeutics PLC (AIM:STX, OTCQB:SHIEF) following the pharmaceutical company's agreement to take full commercial control of its main United States (US) product from Viatris. The broker kept its target price at 23 pence, implying potential upside of 318% from current share price of about 5.5 pence.
3 Generic Drug Stocks to Watch Amid Improving Industry Trends
The Medical - Generic Drugs industry gains from new launches, biosimilar momentum and portfolio shifts, despite pricing pressure and supply challenges.
Here's Why Viatris (VTRS) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Viatris Inc. (VTRS) Q2 2026 Earnings Call Transcript
Viatris Inc. (VTRS) Q2 2026 Earnings Call Transcript
Viatris Inc (VTRS) Shares Fall 7.6% -- GF Value Says Still Overvalued
On August 06, 2026, Viatris Inc (VTRS) shares fell 7.6%, closing at $16.29. Over the past year, the stock has seen significant volatility, with a 52-week high o
Viatris Sharpens Focus with Divestiture, Hikes 2026 Outlook
Harrow Inc. (NASDAQ:HROW) on Thursday agreed to acquire Tyrvaya (varenicline solution) nasal spray 0.03 mg from Viatris Inc. (NASDAQ:VTRS).
Similar companies
-
Dr. Reddy's Laboratories Limited
RDY
·
New York Stock Exchange
Compare
-
Moderna, Inc.
MRNA
·
NASDAQ
Compare
-
Elanco Animal Health Incorporated
ELAN
·
New York Stock Exchange
Compare
-
Baxter International Inc.
BAX
·
New York Stock Exchange
Compare
-
Neurocrine Biosciences, Inc.
NBIX
·
NASDAQ
Compare
-
Roivant Sciences Ltd.
ROIV
·
NASDAQ
Compare